Last synced on 11 April 2025 at 11:05 pm

Fluorescence Imaging For Breast Cancer Detection

Page Type
Product Code
Definition
The combination product consists of an optical imaging agent for injection, and a fluorescence imaging device. The product is intended for use in adults with breast cancer as an adjunct for the intraoperative detection of cancerous tissue within the resection cavity following removal of the primary specimen during lumpectomy surgery. The imaging device is used with the imaging drug for fluorescence imaging of the lumpectomy cavity.
Physical State
Medical imaging device coupled with an injectable drug.
Technical Method
The combination product consists of a device constituent that is a fluorescence imaging device and a drug constituent that is an optical imaging agent for injection. The imaging device consists of a Workstation and a Handheld Probe. The Handheld Probe connects to the Workstation’s Light Source via an optical fiber cable. These components are used together to excite the optical imaging agent and capture and display real-time fluorescence images. During surgery, the Handheld Probe is used to scan the lumpectomy cavity for activated drug by delivering 630 ± 5 nm excitation light and measuring the fluorescence emission signal using a camera after filtering through a 662.5 – 737.5 nm bandpass filter. The resulting data is transferred to the Workstation’s Touchscreen via USB cable. The data is analyzed in real-time via calibrated tumor detection software to highlight regions within the lumpectomy cavity that are suspicious of containing residual cancer. The drug is provided in a clear vial which contains 40 mg of pegulicianine, 39.15 mg of mannitol, 3.78 mg of sodium phosphate monobasic monohydrate and 3.16 mg of sodium phosphate dibasic, heptahydrate. The optical imaging is administered intravenously to patients over a ~3-minute period 2-6 hours prior to imaging.
Target Area
Breast tissue during lumpectomy procedures.
Review Panel
General and Plastic Surgery
Submission Type
PMA
Device Classification
Class 3
GMP Exempt?
No
Summary Malfunction Reporting
Ineligible
Implanted Device
No
Life-Sustain/Support Device
No
Third Party Review
Not Third Party Eligible

No Linked CFR Text

The FDA has not linked product code SAW to any particular section of the CFR (Code of Federal Regulations). There are multiple reasons why this might be the case:

  • The product code was created for a class III submission that does not follow the normal PMN or PMA path - e.g., for a device that falls under HDE (Humanitarian Device Exemption) or EUA (Emergency Use Authorization).
  • The FDA has generated the product code for an existing Class III device, as a result of a PMA supplement that modifies the device in a way that it can't fit under the existing product code originally assigned
  • The product code was created for internal use at the FDA, and not for classification or regulatory-related purposes.

Fluorescence Imaging For Breast Cancer Detection

Page Type
Product Code
Definition
The combination product consists of an optical imaging agent for injection, and a fluorescence imaging device. The product is intended for use in adults with breast cancer as an adjunct for the intraoperative detection of cancerous tissue within the resection cavity following removal of the primary specimen during lumpectomy surgery. The imaging device is used with the imaging drug for fluorescence imaging of the lumpectomy cavity.
Physical State
Medical imaging device coupled with an injectable drug.
Technical Method
The combination product consists of a device constituent that is a fluorescence imaging device and a drug constituent that is an optical imaging agent for injection. The imaging device consists of a Workstation and a Handheld Probe. The Handheld Probe connects to the Workstation’s Light Source via an optical fiber cable. These components are used together to excite the optical imaging agent and capture and display real-time fluorescence images. During surgery, the Handheld Probe is used to scan the lumpectomy cavity for activated drug by delivering 630 ± 5 nm excitation light and measuring the fluorescence emission signal using a camera after filtering through a 662.5 – 737.5 nm bandpass filter. The resulting data is transferred to the Workstation’s Touchscreen via USB cable. The data is analyzed in real-time via calibrated tumor detection software to highlight regions within the lumpectomy cavity that are suspicious of containing residual cancer. The drug is provided in a clear vial which contains 40 mg of pegulicianine, 39.15 mg of mannitol, 3.78 mg of sodium phosphate monobasic monohydrate and 3.16 mg of sodium phosphate dibasic, heptahydrate. The optical imaging is administered intravenously to patients over a ~3-minute period 2-6 hours prior to imaging.
Target Area
Breast tissue during lumpectomy procedures.
Review Panel
General and Plastic Surgery
Submission Type
PMA
Device Classification
Class 3
GMP Exempt?
No
Summary Malfunction Reporting
Ineligible
Implanted Device
No
Life-Sustain/Support Device
No
Third Party Review
Not Third Party Eligible

No Linked CFR Text

The FDA has not linked product code SAW to any particular section of the CFR (Code of Federal Regulations). There are multiple reasons why this might be the case:

  • The product code was created for a class III submission that does not follow the normal PMN or PMA path - e.g., for a device that falls under HDE (Humanitarian Device Exemption) or EUA (Emergency Use Authorization).
  • The FDA has generated the product code for an existing Class III device, as a result of a PMA supplement that modifies the device in a way that it can't fit under the existing product code originally assigned
  • The product code was created for internal use at the FDA, and not for classification or regulatory-related purposes.